Scotland's new consultation draft updates cardiovascular guidance, emphasizing the waist-to-height ratio, patient consent, and a six-month medication review.
On 28 September 2026, the Scottish Government published a detailed consultation paper focused on cardiovascular risk reduction. This draft updates prescribing guidance for adults and introduces a modernized approach to assessing metabolic health. Instead of relying solely on standard weight measurements, the guidance recommends a more nuanced evaluation process for patients. The consultation remains open for public and professional feedback until 20 November 2026.
A central element of the draft is a strong recommendation regarding patient communication in clinical settings. The document suggests that clinicians ask for permission before discussing weight, obesity, or central adiposity. It also advises seeking verbal consent before taking any physical measurements during a standard medical appointment. This proposed shift aims to transition the initial interaction from a mandatory physical assessment to a collaborative conversation between patient and provider.
The guidance also proposes significant changes to how modern treatments are monitored over time. It introduces a specific six-month treatment review point for weight-management prescriptions. If a patient does not lose at least 5% of their initial body weight within six months, the medication should be stopped. This proposed threshold aims to ensure that medical interventions are only continued when they demonstrate measurable clinical effectiveness.
The consultation paper shifts how clinicians measure and interpret changes in overall body composition. For decades, the medical community has used Body Mass Index as the primary screening tool for assessing patient health. However, the Scottish document explicitly notes the distinct limitations of relying on this single measurement metric. The draft cautions that standard index scores cannot distinguish lean muscle mass from fat mass during an evaluation.
This biological distinction is critical for accurately evaluating true metabolic health and predicting long-term cardiovascular risk. To address this limitation, the draft recommends using the waist-to-height ratio alongside standard measurements for adults with an index below 35 kg/m². This dual-measurement combination helps clinicians predict risks for type 2 diabetes, hypertension, and cardiovascular disease more accurately. The paper states that it may be reasonable to assume excess adiposity without additional measurements for those with scores of 35 kg/m² or above.
A high waist-to-height ratio often indicates central adiposity, which is a well-documented driver of complex metabolic complications. Central adiposity refers to excess fat stored around the internal organs, which directly impacts metabolic function and circulatory health. The consultation paper categorizes these waist-to-height ratios into distinct and highly actionable clinical risk bands. It describes a ratio between 0.4 and 0.49 as the healthy and optimal physiological range for adults.
Ratios between 0.5 and 0.59 signal an increased risk of developing cardiovascular issues over time. Furthermore, a ratio of 0.6 or above indicates the highest risk category for severe metabolic disease and heart complications. Individuals in the two higher categories will likely need to implement structured lifestyle adjustments to protect their long-term health. The guidance frames cardiovascular disease as a largely preventable condition when these specific physical risk factors are properly managed.
The paper identifies a healthy diet, regular physical activity, stress management, and tobacco avoidance as key modifiable risk factors. When lifestyle adjustments require additional medical support, incretin-based medicines can assist in reducing severe cardiovascular risk. Integrating medication with sustainable daily habits is often discussed in practical guides to energy balance. The paper cites robust clinical trials, including the SELECT trial, which demonstrated reduced adverse cardiovascular outcomes with semaglutide.
It also highlights the SUMMIT trial, which showed significantly reduced heart-failure events with tirzepatide treatment. These recent clinical trials illustrate how modern treatments can directly address the underlying physiological mechanisms of circulatory disease. Medical strategies are increasingly prioritizing these deep metabolic markers rather than focusing exclusively on total body weight reduction.
Mainstream media often presents medical guidelines as immediate, binding rules for all patients and active healthcare practitioners. In reality, the Scottish document is a consultation paper rather than a finalized, enforceable prescribing policy. The precise wording and specific clinical protocols will likely evolve before the final version is officially implemented nationwide. The paper acknowledges significant delivery challenges across health boards, including variation in specialist services and ongoing medicine supply issues.
Much public attention has focused heavily on the proposed six-month medication stopping criterion found in the draft table. The document states that treatment should stop if a patient is unable to lose at least 5% of their initial body weight. However, the document also emphasizes that clinical decisions must remain highly individualized based on specific patient context. Readers should not interpret this as a rigid rule that automatically ignores a patient's overall metabolic progress.
The guidance stresses the importance of respectful communication to directly counter systemic weight bias in clinical environments. The paper notes that weight stigma remains a major obstacle to obesity treatment among healthcare professionals and active policymakers. To promote compassionate care, the draft endorses a person-centred clinical framework for all routine health consultations. Clinicians are strongly encouraged to follow the "5 As" approach: ask, assess, advise, agree and assist during treatment planning.
This structured framework ensures that patients remain active participants in defining their own medical care and recovery strategies. Clinicians who assess patients carefully can provide targeted advice that aligns with the patient's lived experience and specific capabilities. Agreeing on a plan ensures that the prescribed assistance is realistic, sustainable, and free from counterproductive judgment. Similar principles are reflected in recent clinical guidance for treating overweight adults across other major healthcare organizations.
Furthermore, the paper clearly distinguishes between general clinical indications and pragmatic, phased implementation plans. The general clinical indication includes adults with an index above 30 kg/m² and at least one weight-related comorbidity. In contrast, the first implementation group focuses on people with a score above 38 kg/m² and an obesity-related condition. This phased approach is explicitly described as a practical way to limit severe service variation between different health boards.
Semaglutide and tirzepatide are the two medicines currently identified as approved by the Scottish Medicines Consortium for obesity treatment. Additionally, semaglutide was accepted for use within NHS Scotland in June 2026 for specific cardiovascular risk indications. This secondary approval applies to adults with established cardiovascular disease and either obesity or a minimum index of 27 kg/m². However, local clinical pathways are still in development, meaning treatment access will depend heavily on regional health infrastructure capacity.
The clinical data supporting these recommendations highlights both the efficacy and the strict limitations of current pharmacological treatment. According to a research summary referencing the STEP 1 extension, participants experienced substantial body composition changes during active medication use. During 68 weeks of semaglutide treatment, patients achieved a significant average weight reduction of 17.3%. The Scottish paper notes that trials found greater outcomes when these medicines were combined with targeted non-pharmacological therapies.
Despite these initial positive results, the data on medication withdrawal reveals significant physiological challenges regarding long-term weight maintenance. After stopping semaglutide, participants in the STEP 1 extension rapidly regained 11.6 percentage points of their lost body weight. This post-treatment rebound left affected patients with an average net loss of only 5.6% overall. The Scottish draft directly acknowledges that a significant proportion of people regain some weight if treatment is stopped altogether.
Evidence and clinical guidance on stopping medication remain surprisingly limited, which severely complicates the proposed six-month discontinuation rule. To manage this clinical uncertainty, the draft recommends finding the lowest effective dose once a patient's weight has finally stabilized. This careful tapering strategy aims to maintain vital cardiovascular benefits while minimizing long-term medication dependence and potential drug side effects. Understanding why weight loss plateaus happen is critical for patients navigating this maintenance phase.
As the Scottish Government processes public feedback ahead of the November 2026 deadline, the broader medical community will be watching. Future clinical research must address the clear gap in medication maintenance protocols and the documented risk of weight regain. Medical professionals and health systems must determine how to balance strict clinical thresholds with highly individualized patient responses. The ongoing development of local clinical pathways will ultimately dictate how these draft guidelines translate into everyday medical practice.
Until finalized prescribing pathways emerge, patients considering weight-management medications should prioritize open, transparent discussions with their healthcare team. Understanding the long-term maintenance plan is just as critical as reaching the initial six-month treatment target. A comprehensive approach to cardiovascular health requires sustainable daily habits, respectful clinical support, and highly realistic patient expectations. The final guidance document will ideally reflect this careful balance between rigorous clinical evidence and deeply compassionate patient care.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
